BioNTech (BNTX) Projected to Release Quarterly Earnings on Tuesday

BioNTech (NASDAQ:BNTX) is expected to be announcing its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect BioNTech to post earnings of $0.8470 per share and revenue of $1.17 billion for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%. The firm had revenue of $122.31 million for the quarter, compared to analysts’ expectations of $180.18 million. During the same period in the prior year, the firm earned ($1.60) earnings per share. BioNTech’s revenue was down 59.5% compared to the same quarter last year. On average, analysts expect BioNTech to post ($6.62) EPS for the current fiscal year and ($5.30) EPS for the next fiscal year.

BioNTech Stock Performance

NASDAQ BNTX opened at $86.86 on Tuesday. The company has a fifty day moving average price of $98.36 and a 200-day moving average price of $97.44. The firm has a market cap of $21.97 billion, a price-to-earnings ratio of -11.09 and a beta of 1.25. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. BioNTech has a 1 year low of $79.52 and a 1 year high of $124.00.

Insiders Place Their Bets

In related news, CEO Ugur Sahin sold 36,209 shares of BioNTech stock in a transaction that occurred on Friday, October 9th. The stock was sold at an average price of $95.37, for a total transaction of $3,453,252.33. Following the sale, the chief executive officer directly owned 36,209 shares in the company, valued at $3,453,252.33. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 807,209 shares of company stock worth $79,246,837. Insiders own 19.20% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on BNTX shares. Argus assumed coverage on shares of BioNTech in a research note on Thursday, October 8th. They issued a “hold” rating for the company. Morgan Stanley cut their target price on BioNTech from $115.00 to $114.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 7th. UBS Group restated a “buy” rating on shares of BioNTech in a research note on Wednesday, September 16th. Citigroup decreased their price target on BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a research report on Wednesday, August 5th. Finally, BMO Capital Markets downgraded BioNTech from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $128.00 to $105.00 in a research note on Tuesday, September 8th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, BioNTech presently has an average rating of “Moderate Buy” and an average price target of $125.80.

About BioNTech

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing medicines and vaccines based on messenger RNA and other immunotherapy technologies. The company’s research programs address cancer, infectious diseases, and other serious medical conditions.

BioNTech’s oncology portfolio includes individualized and off-the-shelf cancer immunotherapies, including mRNA-based treatments, cell therapies, antibody-based therapies, and immune-modulating approaches. Its infectious-disease activities include vaccine programs developed through proprietary platforms and collaborations.

In collaboration with Pfizer, BioNTech developed Comirnaty, an mRNA-based COVID-19 vaccine.